Istradefylline effect on Parkinson’s Disease Tremor, Motor symptoms and non-Motor symptoms.
Objective: Istradefylline is FDA approved for use in patients with PD treated with carbidopa-levodopa to reduce off time. GUH Movement Disorder Group has observed that…Impact of istradefylline on the onset of dyskinesia in Parkinson’s Disease patients with wearing off: a randomized controlled study (ODYSSEI)
Objective: To determine the effect of long-term treatment with istradefylline (IST) on the time to onset of dyskinesia in Parkinson’s disease (PD) patients with wearing-off…The development of a multiplex allele specific PCR to improve the diagnostic yield of NGS in the GBA gene screening
Objective: Our aim is to offer a complete and reliable diagnostic service excluding false negative. Background: Heterozygous variants in the GBA gene are the most…Effect of KW-6356, a novel adenosine A2A receptor antagonist/inverse agonist, on motor and non-motor symptoms in Parkinson’s disease patients as an adjunct to levodopa therapy: Results of Phase 2b study
Objective: To evaluate the efficacy and safety of KW-6356 in Parkinson’s disease (PD) patients with levodopa therapy, irrespective of the presence of wearing-off (WO). Background:…Levodopa-induced unilateral orofacial dystonia in multiple system atrophy : case report and video presentation
Objective: The study reports a case of lateral orofacial dystonia in a multiple system atrophy (MSA) patient treated with levodopa, and discusses the clinical characteristics…Impact of istradefylline on the adjustment of levodopa dose escalation in Parkinson’s disease: Results of the ISTRA ADJUST PD randomized, controlled study
Objective: To evaluate the effect of istradefylline (IST), an adenosine A2A receptor antagonist, on the adjustment of levodopa dose escalation in patients with Parkinson’s disease…Istradefylline/L-DOPA combination therapy for Parkinson’s disease and blood markers of glycolytic energy homeostasis
Objective: To clarify the potential to preserve glycolytic energy homeostasis (GEH) with the Istradefylline combined to L-DOPA (IST-LD), and to prevent LD-induced weight loss and…Clinical and neurological features of the course of parkinsonism in the presence of chronic renal disease
Objective: To study the clinical and neurological features of the course of parkinsonism in chronic renal disease. Background: Under our supervision were 30 patients with…Blood hexokinase reduction in de novo Parkinson’s disease and remodeling of glycolytic energy homeostasis with L-DOPA/Istradefylline combination therapy
Objective: To evaluate the glycolytic energy homeostasis in Parkinson’s disease (PD), and to define the effects of PD pharmacotherapies on glycolytic dynamics Background: Neuronal energy…Efficacy and safety of istradefylline in Parkinson’s disease patients with postural abnormality: Results from a multicenter, open-label study in Japan
Objective: To investigate the efficacy and safety of istradefylline for the treatment of postural abnormality in patients with Parkinson’s disease (PD). Background: Postural abnormality in…